An epidermal growth factor receptor-targeting immunotoxin based on IgG shows potent antitumor activity against head...

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Epidermal growth factor receptor (EGFR) is a key target in head and neck cancer (HNC) therapy.
• Existing anti-EGFR therapies face limitations due to drug resistance.
• There is a need for alternative therapeutic strategies for EGFR-positive HNC.

Purpose of the Study:

• To develop a novel EGFR-targeting immunotoxin, CTX-LR-LO10, to overcome resistance.
• To evaluate the efficacy and mechanisms of action of CTX-LR-LO10 in HNC models.
• To explore CTX-LR-LO10 as a potential new therapeutic agent.

Main Methods:

• Developed an immunotoxin (CTX-LR-LO10) by conjugating cetuximab (CTX) with a Pseudomonas exotoxin A fragment (LR-LO10) using site-specific conjugation.
• Assessed binding affinity, stability, immune cell interactions, and pharmacokinetics of CTX-LR-LO10.
• Evaluated in vitro effects on EGFR-positive HNC cells (protein synthesis inhibition, apoptosis, migration, invasion).
• Tested in vivo efficacy in xenograft mouse models.
• Performed transcriptome analysis to understand immune responses and gene expression changes.

Main Results:

• CTX-LR-LO10 demonstrated specific binding to EGFR and retained IgG properties.
• The immunotoxin inhibited protein synthesis and induced apoptosis, reduced migration and invasion in HNC cells.
• CTX-LR-LO10 showed superior tumor suppression compared to CTX or LR-LO10 in mouse models.
• Transcriptome analysis indicated immune response activation and altered gene expression related to its mechanism.

Conclusions:

• CTX-LR-LO10 is a potent EGFR-targeting immunotoxin with significant preclinical efficacy.
• The novel immunotoxin overcomes limitations of existing therapies and warrants further investigation.
• CTX-LR-LO10 represents a promising new therapeutic candidate for EGFR-positive cancers.